Incentives for phase 1 clinical trials, cost advantage will help India to tap global opportunity: Parexel India MD Sanjay Vyas
Pharmaceutical industry in India is now looking beyond opportunities in the generics space and focusing on new avenues including biosimilars, contract manufacturing. India’s skillsets in R&D
